PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice

Germline BRCA1/2 mutations account for about 10% of all breast cancer. BRCA1/2 proteins are involved in homologous recombination - DNA double-strand break repair mechanism. Poly-(ADP ribose) polymerases (PARP) are required to repair DNA single-strand breaks through base excision repair. PARP inhibit...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	M. A. Frolova, E. V. Glazkova, M. B. Stenina
Aineistotyyppi:	Artigo
Kieli:	Russo
Julkaistu:	Remedium Group LLC 2020-07-01
Sarja:	Медицинский совет
Aiheet:	brca-associated breast cancer parp inhibitors metastatic triple negative breast cancer olaparib talazoparib
Linkit:	https://www.med-sovet.pro/jour/article/view/5701
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!